Cargando…
Preclinical efficacy of dual mTORC1/2 inhibitor AZD8055 in renal cell carcinoma harboring a TFE3 gene fusion
BACKGROUND: Renal cell carcinomas (RCC) harboring a TFE3 gene fusion (TfRCC) represent an aggressive subset of kidney tumors. Key signaling pathways of TfRCC are unknown and preclinical in vivo data are lacking. We investigated Akt/mTOR pathway activation and the preclinical efficacy of dual mTORC1/...
Autores principales: | Kauffman, Eric C., Lang, Martin, Rais-Bahrami, Soroush, Gupta, Gopal N., Wei, Darmood, Yang, Youfeng, Sourbier, Carole, Srinivasan, Ramaprasad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6743205/ https://www.ncbi.nlm.nih.gov/pubmed/31519159 http://dx.doi.org/10.1186/s12885-019-6096-0 |
Ejemplares similares
-
Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro
por: Jordan, Nicola J, et al.
Publicado: (2014) -
Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma
por: Naing, A, et al.
Publicado: (2012) -
The mTOR inhibitor AZD8055 inhibits proliferation and glycolysis in cervical cancer cells
por: LI, SHAORU, et al.
Publicado: (2013) -
In Vitro and In Vivo Interactions of TOR Inhibitor AZD8055 and Azoles against Pathogenic Fungi
por: Sun, Yi, et al.
Publicado: (2022) -
Anti-tumor effect of AZD8055 against bladder cancer and bladder cancer-associated macrophages
por: Hu, Weimin, et al.
Publicado: (2023)